Effectiveness and Safety of Omalizumab in Children With Allergic Asthma.
Completed
Conditions studied: Allergic Asthma
In brief
The study was the non-interventional, retrospective study aimed to assess the effectiveness and safety of omalizumab in children with allergic asthma in China, and described patient profiles and treatment patterns of omalizumab in real-world practice.
Key facts
- Study ID
- NCT05424523
- Run by
- Novartis Pharmaceuticals
- People needed
- 200
- Starts
- 2021-02-25
- Expected to finish
- 2021-06-28
- Last updated by the study team
- 2022-07-05
Who can join
Age: 6 and older, up to 11. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Aged between 6 -<12 years
- Diagnosed with allergic asthma and could be treated using omalizumab. Comorbidities included allergic rhinitis, atopic dermatitis, nasal polyp, chronic urticaria, and food allergy
- Received omalizumab during the identification period
- Had at least one documented follow-up data after omalizumab treatment
- Provided informed consent if required by ethics committee (EC) of hospital
You may not qualify if…
- Current participation in a clinical trial of any investigational treatment
Where it is running
- Novartis Investigative Site — East Hanover, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.